The aberrant accumulation of b-amyloid peptide (Ab) in the brain is a key feature of Alzheimer's disease (AD), and enhanced cleavage of b-amyloid precursor protein (APP) by b-site APP-cleaving enzyme 1 (BACE1) has a major causative role in AD. Despite their prominence in AD pathogenesis, the regulation of BACE1 and APP is incompletely understood. In this study, we report that the circular RNA circular RNA sponge for miR-7 (ciRS-7) has an important role in regulating BACE1 and APP protein levels. Previous studies have shown that ciRS-7, which is highly expressed in the human brain, is down-regulated in the brain of people with AD but the relevance of this finding was not clear. We have found that ciRS-7 is not involved in the regulation of APP and BACE1 gene expression, but instead reduces the protein levels of APP and BACE1 by promoting their degradation via the proteasome and lysosome. Consequently, overexpression of ciRS-7 reduces the generation of Ab, indicating a potential neuroprotective role of ciRS-7. Our data also suggest that ciRS-7 modulates APP and BACE1 levels in a nuclear factor-jB (NF-jB)-dependent manner: ciRS-7 expression inhibits translation of NF-jB and induces its cytoplasmic localization, thus derepressing expression of UCHL1, which promotes APP and BACE1 degradation. Additionally, we demonstrated that APP reduces the level of ciRS-7, revealing a mutual regulation of ciRS-7 and APP. Taken together, our data provide a molecular mechanism implicating reduced ciRS-7 expression in AD, suggesting that ciRS-7 may represent a useful target in the development of therapeutic strategies for AD.
Introduction
Alzheimer's disease (AD) is the most prevalent form of dementia, and accumulation of b-amyloid peptide (Ab) is a key pathogenic factor in AD. Mounting evidence suggests that reduction of brain Ab, either by directly reducing its production and aggregation or by promoting its degradation and clearance, could ameliorate AD pathology [1] [2] [3] . Amyloid precursor protein (APP) is a type I oriented membrane protein that is committed to the amyloidogenic pathway by b-site APP cleaving enzyme 1 (BACE1) [4] , which mediates the initial and rate-limiting processing step leading to Ab generation. On one hand, the degradation of APP can efficiently reduce the generation of Ab; on the other, the degradation of BACE1 can inhibit amyloidogenic processing of APP [5] . It has been reported that proteasome inhibitors resulted in an increase in APP C99 levels, suggesting that APP processing at the b-secretase site may be affected by the ubiquitin-proteasome pathway [6] .
Ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) is an abundant neuronal enzyme that has been demonstrated to promote cell viability and maintain neuronal integrity [7] . UCHL1 plays a regulatory role in targeting proteins for proteasome degradation by two enzymatic activities, one that removes and recycles ubiquitin molecules from the degraded proteins to generate free monomeric ubiquitin, and another that links ubiquitin molecules, thus generating polyubiquitin chains that tag proteins for disposal [8] . It has been reported that UCHL1 promotes APP and BACE1 ubiquitination and proteasome degradation [9] . Sequence analysis revealed several putative regulatory elements including nuclear factor-jB (NF-jB) in the UCHL1 promoter [10] . In addition, NF-jB level is increased and UCHL1 level is decreased in sporadic AD patients. NF-jB signaling plays an important role in gene regulation and is implicated in cell apoptosis, inflammation and oxidative stress in AD [11] .
Circular RNA (circRNA) are drawing increased attention among the noncoding RNA species. Novel studies involving deep sequencing and bioinformatics analysis have identified thousands of circRNA in the past several years and begun to crack the enigma of their cellular function. circRNA are generated during splicing through various mechanisms such as backsplicing pre-mRNA transcripts and exon-skipping events, leading to formation of exons (exonic circRNA) or introns (intronic circRNA), some of which are highly abundant, evolutionarily conserved and tissue specific [12, 13] . Evidence is emerging that some circRNA play roles in transcriptional control. circRNA that contain introns have been identified as regulating gene transcription in cis by forming specific interactions with the U1 small nuclear ribonucleoprotein RNA, suggesting that circRNA are involved in transcription regulation [14] . Cerebellar degeneration-related protein 1 (CDR1) natural antisense transcript (NAT), which produces a circular exonic RNA that appears to stabilize the CDR1 mRNA, is highly abundant in human and mouse brain [15] . Previous studies have made substantial progress in the function of CDR1 NAT in acting as an miR-7 sponge in vitro and in vivo, and this circular transcript has thus been termed circular RNA sponge for miR-7 (ciRS-7) [16, 17] . In addition, it has been revealed that ciRS-7 is bound by the miRNA effector protein Argonaute and is located in the cytoplasm. However, the biological functions of ciRS-7 remain to be elucidated.
In this study, we have found that ciRS-7 is not involved in the regulation of APP and BACE1 gene expression, but reduces the levels of both proteins by promoting their degradation through the proteasome and lysosome. The level of Ab was consequently decreased suggesting ciRS-7 plays a role in protection of neuronal cells. Moreover, ciRS-7 promotes the expression of UCHL1, which mediates APP and BACE1 degradation, and this effect is mediated by inhibited translation and increased cytoplasmic localization of NF-jB. Also, we demonstrated that APP reduces the level of ciRS-7. Our results revealed a molecular mechanism linking ciRS-7 to AD.
Results

ciRS-7 reduces the protein expression level of APP
It has recently been demonstrated that ciRS-7 was down-regulated in the brain of AD patients [18] . To investigate whether ciRS-7 could affect the expression of APP, we overexpressed ciRS-7 in HEK293T and SH-SY5Y cells to detect the expression levels of APP. qRT-PCR analysis with the transfected cells showed that ciRS-7 expression construct was transcribed and the RNA level of ciRS-7 in both cell lines was significantly increased compared with those of the empty vector (EV) and inverted repeats (ir) construct, which formed only a few ciRS-7, while no endogenous ciRS-7 could be detected in SH-SY5Y cells (Fig. 1A,D) . Furthermore, the protein expression level of APP was assessed by immunoblot and the results revealed that overexpression of ciRS-7 decreased the protein level of APP in both cell lines (Fig. 1B,E) . However, qRT-PCR analysis showed that the mRNA level of APP was unaltered when ciRS-7 was overexpressed in these cells (Fig. 1C,F) . To further confirm this finding, we then used ciRS-7 small interfering RNA (siRNA) to knock down ciRS-7 in HEK293T cells and found that the level of ciRS-7 was drastically decreased compared with the controls (Fig. 1G ). Consequently, the protein level of APP was increased when ciRS-7 was knocked down; however, the mRNA level of APP remained unchanged (Fig. 1H,I ). Taken together, these data show that ciRS-7 reduced the protein level of APP.
ciRS-7 promotes APP degradation by both the proteasome and the lysosome To ascertain whether the decline in APP protein level reflects a reduced protein synthesis or enhanced degradation by ciRS-7, SH-SY5Y cells were overexpressed with ciRS-7 and treated with cycloheximide (CHX), a protein translation inhibitor. Under conditions of expression of the control plasmids in combination with CHX treatment, it was observed that APP protein level decreased in a time-dependent manner, showing a half-life of 2 h ( Fig. 2A,B) . Furthermore, the reduction in the APP protein was more pronounced 2 h after ciRS-7 overexpression in the presence of CHX ( Fig. 2A,B) . The additive reduction in the protein expression level of APP by overexpression of ciRS-7 suggests that ciRS-7-induced reduction in APP protein level is not mediated by an inhibition of protein translation.
Given the evidence that ciRS-7 reduced the protein level of APP, but had no effect on protein translation, we next investigated whether ciRS-7 affects the stability of APP in neuronal cells. To that end, SH-SY5Y cells were overexpressed with ciRS-7 treated with MG132, a proteasome inhibitor, to prevent proteasome-mediated protein degradation. Immunoblot analysis demonstrated that MG132 treatment increased the APP protein levels compared with the vehicle control, suggesting that APP can be degraded by the proteasome. Conspicuously, ciRS-7-induced APP decline could be blocked by MG132 treatment (Fig. 2C) . These data indicate that ciRS-7 reduces the protein level of APP through a proteasome-dependent process.
It has been reported that transmembrane protein can also be degraded by the lysosome [7] . To investigate whether ciRS-7 reduces the level of APP, a transmembrane protein, by the lysosome, SH-SY5Y cells were overexpressed with ciRS-7 and then treated with chloroquine (Chl), a specific lysosome inhibitor. As shown in Fig. 2D , lysosomal inhibition resulted in ) APP protein and mRNA levels of the transfected HEK293T cells were measured by immunoblot and qPCR, respectively. b-Actin served as the loading control of immunoblot, and quantification was performed with Quantity One software. GAPDH was used as internal control for qPCR. The data are expressed as the mean AE SEM for triplicate experiments (n = 3). Statistical analysis was performed using either Student's t test (two-group comparison) or one-way analysis of variance (more than two groups). *P < 0.05. enhanced protein level of APP, showing an attenuated effect of ciRS-7 on APP. Our results indicate that ciRS-7 promotes the degradation of APP via the lysosomal pathway as well. Taken together, ciRS-7 reduces the protein level of APP through both the proteasomal and lysosomal pathways.
ciRS-7 reduces BACE1 protein level and Ab generation
b-Cleavage of APP by BACE1 mainly initiates Ab generation in the amyloidogenic pathway. The present study sought to examine the efficacy of ciRS-7 on the expression of BACE1. To that end SH-SY5Y cells were overexpressed with ciRS-7 and qRT-PCR analysis was performed to investigate whether the transcribed mRNA expression level of BACE1 was affected by ciRS-7. As shown in Fig. 3A , the mRNA level of BACE1 was not altered in ciRS-7-overexpressed cells compared with those from the control cells. The protein expression level of BACE1 was further assessed by immunoblot and the result demonstrated the mature BACE1 protein level was slightly decreased, and the ir construct formed only a few ciRS-7, compared with the EV control. However, overexpression of ciRS-7 significantly reduced the mature protein level of BACE1 (Fig. 3B) . Interestingly, the immature form of BACE1 was significantly reduced when ir or ciRS-7 construct was transfected, indicating ciRS-7 also reduces the immature BACE1 protein. To further confirm whether ciRS-7 affects the protein synthesis of BACE1, SH-SY5Y cells were overexpressed with ciRS-7 and were treated with CHX. Immunoblot analysis to detect the BACE1 protein revealed that the level of BACE1 decreased in a time-dependent manner upon treatment with CHX, showing a half-life of 4 h. Furthermore, the reduction of BACE1 protein was more pronounced and the half-life was decreased to 2 h when ciRS-7 was overexpressed (Fig. 3C,D) , indicating that ciRS-7-induced decline in BACE1 protein was not mediated by an inhibition of protein translation. However, when SH-SY5Y cells were transfected with ciRS-7 and subsequently treated with MG132 or Chl, the treatment of MG132 or Chl could significantly inhibit the decline of BACE1 protein induced by ciRS-7 ( Fig. 3E,F) , suggesting that ciRS-7 promotes BACE1 degradation through both the proteasomal and lysosomal pathways.
b-site APP cleaving enzyme 1cleaves APP at the bsecretase site in vivo [6] . The present study has revealed that ciRS-7 promotes BACE1 degradation via the proteasomal and lysosomal pathways. To further examine whether ciRS-7 affects the proteolytic processing of APP by BACE1 and the subsequent Ab production, we overexpressed ciRS-7 and the APP Swedish mutant (APPsw) in SH-SY5Y cells and then treated the cells with BACE1 inhibitor (BI) LY2831176. Immunoblot analysis was performed on the cell lysates to detect APP C83 and C99, the a-and b-secretase cleavage products. The results showed, in the vehicle treated cells, ciRS-7 reduced the protein level of APPsw, which is consistent with previous results shown in Fig. 1E . In addition, C99 was decreased by ciRS-7 compared with EV or ir controls. When cells were treated with BI, the levels of neuregulin (NRG), a natural BACE1 substrate [19] , were enhanced compare with those under vehicle treatment, indicating that activity of BACE1 can be inhibited by BI. Furthermore, the intensity of C99 reduction by ciRS-7 was lower than that under vehicle treatment (Fig. 3G,H) , suggesting that C99 reduction is due to ciRS-7-induced reduction of APP amyloidogenic processing and a general reduction of APPsw. Notably, ciRS-7 reduces the level of both APPsw and C99, but does not affect the level of C83, suggesting that ciRS-7 could regulate the a-secretase. We then treated the transfected cells with TAPI to inhibit a-secretase activity. The results of an immunoblot showed that C83 protein levels are decreased compared with those under vehicle treatment. However, when ciRS-7 was overexpressed, the C83 level was increased compared with EV or ir controls (Fig. 3G,H) , suggesting that ciRS-7 promotes the non-amyloidogenic pathway of APP. Additionally, we detected Ab40 and Ab42 levels in the conditioned media and the data showed that overexpression of ciRS-7 decreased the levels of Ab40 and Ab42 compared with controls (Fig. 3I) . Taken together, the data showed that ciRS-7 inhibits the b-secretase cleavage of APP and the subsequent Ab generation.
ciRS-7 promotes degradation of BACE1 and APP through UCHL1
Ubiquitin carboxyl-terminal hydrolase L1 accelerates degradation of APP and BACE1 by both the proteasomal and lysosomal pathways [7, 9] . Since previous work has shown that UCHL1 expression is decreased in different cellular models and in sporadic AD brains, we therefore investigated the effect of ciRS-7 on UCHL1. We overexpressed ciRS-7 in SH-SY5Y cells and found that overexpression of ciRS-7 up-regulated the mRNA and protein levels of UCHL1 (Fig. 4A,B) , suggesting that ciRS-7 is involved in the expression of UCHL1. To further investigate whether the reduction of APP and BACE1 by ciRS-7 was mediated by UCHL1, we used two siRNAs to knock down the expression of UCHL1 in SH-SY5Y cells. qRT-PCR and immunoblot analysis revealed that the mRNA and protein level of UCHL1 was drastically decreased compared with the negative control (Fig. 4C,D) . Consequently, the reduction of APP and BACE1 proteins by ciRS-7 was abolished when UCHL1 was knocked down (Fig. 4E,F) , suggesting that the reduction of APP and BACE1 by ciRS-7 was mediated by UCHL1.
ciRS-7 up-regulates UCHL1 expression by regulating NF-jB
It has been reported that NF-jB acts as a transcription regulator for downstream targets, for instance the À300 to À109 bp NF-jB binding sequences in the UCHL1 gene promoter [10] , and activation of NF-jB signaling by tumor necrosis factor-a (TNF-a) negatively regulates UCHL1 gene transcription [20] .
As our results have revealed that ciRS-7 regulates UCHL1 gene expression, we next investigated whether ciRS-7-mediated regulation of UCHL1 gene transcription is dependent on NF-jB. To that end SH-SY5Y cells were firstly cotransfected with a pUCHLl-D luciferase reporter construct driven by a promoter harboring the NF-jB binding sequences in the UCHL1 gene [20] , together with ciRS-7 expression and control constructs. The cells were then treated with TNF-a, which promotes the binding of NFjB to the response sequences and subsequently The conditioned media of the transfected SH-SY5Y cells were harvested and ELISA was performed to detect Ab42 and Ab40; mat, mature; im, immature. b-Actin was used as a loading control for the immunoblot, and quantification was performed with Quantity One software. The data are expressed as the mean AE SEM for triplicate experiments (n = 3). Statistical analysis was performed using either Student's t test (two-group comparison) or one-way analysis of variance (more than two groups). *P < 0.05.
inhibits UCHL1 promoter activity [20] . However, we found that overexpression of ciRS-7 enhanced the luciferase activity (Fig. 5A ), indicating that ciRS-7 releases NF-jB-inhibited UCHL1 promoter activity. Furthermore, we overexpressed ciRS-7 in SH-SY5Y cells and treated them with 25 lM BAY117082, a specific NF-jB inhibitor, and subsequently detected the expression level of UCHL1. The results of qRT-PCR and immunoblot showed that overexpression of ciRS-7 significantly increased both the mRNA and protein levels of UCHL1 as compared with the controls, but no longer altered the mRNA and protein levels of UCHL1 when NF-jB was inhibited (Fig. 5B,C) , suggesting that NF-jB mediates the effect of ciRS-7 on UCHL1 expression. Therefore, we further investigated whether ciRS-7 could affect NF-jB. As shown in Fig. 5D , when ciRS-7 was overexpressed in SH-SY5Y cells, the mRNA level of p65
was not altered; however, the p65 protein level was significantly decreased (Fig. 5E ).
To explore whether ciRS-7 affects p65 protein synthesis, we treated SH-SY5Y cells with CHX. Immunoblots showed that p65 had the same decreasing trend and halflife (12 h) in the absence or presence of ciRS-7 overexpression (Fig. 5F ), suggesting that ciRS-7 inhibits p65 protein synthesis. It is known that, upon activation, NF-jB translocates into the nucleus and there activates or inhibits the transcription of target genes. Therefore, we perform confocal microscopy to investigate whether ciRS-7 could alter the subcellular localization of NF-jB. When SH-SY5Y cells were treated with TNF-a, NF-jB was located mostly in the nucleus whereas ectopic expression of ciRS-7 facilitated localization of most NFjB in the cytoplasm (Fig. 5G) , indicating that either ciRS-7 promotes the shift of NF-jB from the nucleus to the cytoplasm or ciRS-7 prevents the migration of NF-jB to . (E, F) SH-SY5Y cells were transfected with two UCHL1 siRNAs for 24 h. The cells were then transfected with ciRS-7 plasmid or control plasmids for an additional 48 h. Cell lysates were used to detect APP and BACE1 protein levels by immunoblot (E) and they were quantified (F). b-Actin was used as a loading control of immunoblot, and quantification was performed with Quantity One software. The data are expressed as the mean AE SEM for triplicate experiments (n = 3). Statistical analysis was performed using either Student's t test (two-group comparison) or one-way analysis of variance (more than two groups). *P < 0.05. the nucleus. Taken together, these results showed that ciRS-7 suppresses NF-jB protein synthesis and induces its cytoplasmic localization, thus promoting UCHL1 expression and UCHL1-induced APP and BACE1 ubiquitination and degradation.
APP decreases the level of ciRS-7
Given the evidence that ciRS-7 down-regulates the expression of APP, we explored whether APP could affect ciRS-7. To that end we detected ciRS-7 in TNF-a for 36 h and stained with antibody against p65.The expression and translocation of p65 were determined by confocal immunofluorescence. DAPI staining was used to identify the cell nucleus. Immunoblot quantification was performed with Quantity One software. The data are expressed as the mean AE SEM for triplicate experiments (n = 3). Statistical analysis was performed using either Student's t test (two-group comparison) or one-way analysis of variance (more than two groups). *P < 0.05.
HEK293T and 20E2 cells that stably overexpress APPsw. qRT-PCR showed that the level of ciRS-7 was significantly decreased in 20E2 cells compared with that in HEK293T cells (Fig. 6A ). In addition, we overexpressed ciRS-7 and APP in SH-SY5Y cells and subsequently detected ciRS-7. qRT-PCR analysis revealed that ciRS-7 was expressed in SH-SY5Y cells and overexpression of APP reduced the level of ciRS-7 (Fig. 6B) . To further confirm this finding, we then used two siRNAs to knock down APP in HEK293T cells and found that the level of APP was drastically decreased compared with the control and, as a consequence, the level of ciRS-7 was increased when APP was knocked down (Fig. 6C) . Taken together, the data showed that APP down-regulates the level of ciRS-7, revealing a mutual regulation between APP and ciRS-7.
Discussion
In this study, we found that ciRS-7 reduces both the mature and immature forms of BACE1, and the reduction intensity of immature BACE1 is stronger than that of the mature form (Fig. 3B ). This could be caused by the immature structure more easily undergoing post-translational modification by UCHL1 for protesomal and lysosomal degradation. Additionally, the endogenous APP detected in HEK293T and SH-SY5Y cells shows only the mature form. However, when APPsw was overexpressed, the immature form could be detected in SH-SY5Y cells. Our results showed that ciRS-7 mainly affects the degradation of the mature APP. The protesomal and lysosomal degradation of APP and BACE1 were demonstrated to be mediated by UCHL1. Emerging evidence indicates that the activity of UCHL1 is down-regulated in AD brain and the level of UCHL1 is inversely proportional to neurofibrillary tangle numbers in the brain of sporadic patients with AD [21] . In addition, inhibition of UCHL1 significantly enhances BACE1 protein level in a time-dependent manner [9] . Therefore, down-regulation of UCHL1 seems to be at least in part responsible for the pathogenesis of AD. Our results demonstrate that ciRS-7 up-regulates UCHL1 expression, revealing a neuro-protective role of this circRNA. Also, we found that ciRS-7 expression can be detected in the cells transfected with ciRS-7-ir plasmid, suggesting that circularity of ciRS-7 could be regulated by endogenous splicing factors. Further investigation showed that APP can in turn inhibit ciRS-7 expression, indicating that APP or its proteolytic products may regulate splicing factors to alter ciRS-7 biogenesis. In addition, since ciRS-7 can be directly cleaved by miR-671, and a reduced level of ciRS-7 is produced by APP, it could be that APP regulates miRNA and RNA-binding proteins to promote degradation of ciRS-7 [15] . Taken together, our results demonstrate a potential application of ciRS-7 in promoting APP and BACE1 degradation and also provide a new insight into the circRNA regulatory network. Furthermore, these results could explain how deficiency of ciRS-7 may aggravate AD progression. Recently, circRNA have been shown to be widespread and substantial in the eukaryotic tree of life The data are expressed as the mean AE SEM for triplicate experiments (n = 3). Statistical analysis was performed using Student's t test (two-group comparison). *P < 0.05. [22] , but only a few of them have been well-characterized and functionally demonstrated to be microRNA sponges or inhibitors [23] . For instance ciRS-7 acts as a miR-7 sponge and the potential role of ciRS-7 has been explored in myocardial infarction, where it was shown to regulate the protective role of miR-7a in myocardial infarction injury, involving the function of the miR-7a targets poly(ADP-ribose) polymerase and SP1 [24] . Additionally, ciRS-7 inhibits miR-7 function, thus promoting expression of the downstream targets Myrip and Pax6 in islet cells, which in turn improves insulin secretion [25] . It has been reported that deficits in ciRS-7 and ciRS-7 'sponging activities' might be expected to increase ambient miR-7 levels in ADaffected brain cells, to ultimately contribute to the down-regulation of selective miR-7-sensitive mRNA targets [26] . For example, the ubiquitin protein ligase A (UBE2A), a phagocytic protein essential in the clearance of amyloid peptides in AD and other progressive inflammatory degenerations of the human CNS, is depleted in AD brain [27, 28] . In addition, transcription factor NF-jB is involved in the pathogenesis of a range of neurodegenerative disorders including AD. The expression of p65 was identified to be down-regulated by miR-7 in dopaminergic SH-SY5Y cells in a study of Parkinson's disease [29] . In our study, however, the mRNA level of p65 is not affected by ciRS-7, while the protein level and activity of p65 are down-regulated, suggesting the regulation of ciRS-7 on p65 was not through sponging of miR-7, or in other words, ciRS-7 might act as a miR-7 buffer or reservoir in modulating miR-7 function rather than a negative regulator of miR-7.
When we used MG132 to treat SH-SY5Y cells, we found that MG132 cannot rescue the down-regulation of p65 by ciRS-7, which implies that ciRS-7 did not affect the proteasome degradation of p65 [30] . In this study, we further showed that ciRS-7 decreased p65 translation. From a newly established web named CircInteractome (freely accessible at http://circinter actome.nia.nih.gov), which provides bioinformatic analyses of binding sites on circRNA and additionally analyzes miRNA and RBP sites in junction and junction-flanking sequences [31] , we found that ciRS-7 has binding sites for fused in sarcoma [FUS; also known as translocated in liposarcoma (TLS)] and insulin-like growth factor-II mRNA binding protein 2 (IGF2BP2, also known as IMP2). Interestingly, IMP2 can mediate mRNA translation by interaction with ribosomal proteins [32] [33] [34] , indicating that ciRS-7 may interact with IMP2 to inhibit p65 translation. Meanwhile, newly found circ-Foxo3, highly expressed in heart samples of aged patients and mice, was found mainly distributed in the cytoplasm, where it interacted with the antisenescent protein ID-1 and the transcription factor E2F1, as well as the anti-stress proteins focal adhesion kinase and hypoxia-inducible factor 1a, all of which are retained in the cytoplasm and could no longer exert their anti-senescent and anti-stress roles, resulting in increased cellular senescence [35] . Therefore, we conducted experiments to determine whether ciRS-7 influences the shuttling of NF-jB from cytoplasm to nucleus and found that ciRS-7 promotes NF-jB's cytoplasmic localization, suggesting an interaction between them. Since it has been known that FUS can act as a coactivator of NF-jB to play a pivotal role in NF-jB-mediated transactivation [36] , FUS matches flanking regions of ciRS-7, and abnormal aggregation of FUS protein has been reported in multiple neurodegenerative diseases [37, 38] , ciRS-7 may interact with FUS to regulate NF-jB localization and activity. However, the interaction between ciRS-7 and NF-jB needs to be further investigated.
Due to the stability and RNaseR resistance of circRNA, the circRNA hsa_circ_0001649 was found to have novel biomarker potential for hepatocellular carcinoma [39] . Rybak-Wolf et al. showed that circRNA are highly enriched in the mammalian brain, with specific and dynamic expression during neuronal differentiation. In the process of neuronal differentiation induced by stimulation with retinoic acid in mouse P19 embryo cells and primary neurons, ciRS-7 expression increased from day 2 to day 21, indicating that ciRS-7 is essential for neuronal proliferation and differentiation [40] . Moreover, Westholm et al. [41] noted that Drosophila circRNA, particularly circularizing exons, accumulate to the highest levels in the aging CNS. We assume that the down-regulation of ciRS-7 in the brain may be an indication of AD.
Taken together, ciRS-7 may represent a useful tool in addressing the growing quest for new therapeutic strategies based upon regulation of AD core factors. In this regard, the pathophysiological role of ciRS-7 in AD requires further investigation. Therefore, study of this class of noncoding circRNA has potential therapeutic and research applications. We believe the key future challenge for the field will be to understand the regulation and function of these unusual molecules. Plasmids pcDNA3-ciRS-7-ir and pcDNA3-ciRS-7, were provided by T. Hansen [17] (Aarhus University, Denmark). APP695, APP695-sw and pUCHL1-D constructs were provided by W. Song (University of British Columbia).
Materials and methods
Cell cultures and reagents
Luciferase activity assays
Cells were transfected with ciRS-7 plasmid or control plasmids together with pUCH-L1-D, and 24 h post-transfection the cells were treated with 50 ngÁmL À1 TNF-a for an additional 36 h and harvested to measure the luciferase activity. Renilla luciferase construct was also transfected to normalize the transfection efficiency. Then cells were harvested and lysed with 100 lL passive lysis buffer (Promega, Madison, WI, USA) per well. Firefly and Renilla luciferase activities were measured using the dual-luciferase reporter assay system (Promega). The firefly luciferase activity was normalized to the Renilla luciferase activity and expressed as relative luciferase units (RLU) to reflect the promoter activity.
Transient transfections
SH-SY5Y cells and 293T cells were pre-cultured overnight until 50% confluence and then transfected with plasmids by Lipofectamine 2000 (Invitrogen) following the manufacturer's instructions. At 4-6 h post-transfection, the supernatant of cell cultures was removed and fresh medium was added. After incubation for an additional 48 h, cells were collected for further experiments.
RNA interference
Human ciRS-7, APP and UCHL1 specific and control random siRNA were chemically synthesized by GenePharma Biological Technology (Shanghai, China). Target Table 1 ). Cells were transfected with the siRNA using Lipofectamine MAX according to the manufacturer's instructions (Invitrogen) and were analyzed by qRT-PCR and immunoblot to determine knockdown efficiency.
Protein extraction and immunoblot analysis
Cells were harvested followed by lysis and a fixed amount of protein was loaded on a polyacrylamide gel followed by transfer to a poly(vinylidene difluoride) membrane, followed by incubation with shaking overnight at 4°C with C20 antibody (for APP and APP C-terminal fragments), which was provided by W. Song (University of British Columbia; 1 : 2000 dilution), BACE1 antibody (1 : 1000 dilution, Cell Signaling Technology, Danvers, MA, USA), NF-jB (1 : 1000 dilution, Santa Cruz Biotechnology, Dallas, TX, USA), UCHL1 (1 : 1000 dilution, Cell Signaling Technology), NRG (1 : 1000 dilution, Santa Cruz Biotechnology) diluted in Tris-buffered saline containing 5% milk and 0.1% Tween-20. b-Actin was used as the loading control. After incubation with determined horseradish peroxidase-conjugated secondary antibody, protein expression was detected by using enhanced chemiluminescence (Millipore, Darmstadt, Germany). 
Confocal microscopy
SH-SY5Y cells were distributed per well in a 24-well plate and transfected with ciRS-7. Cultured cells were washed with phosphate-buffered saline (PBS) and fixed with paraformaldehyde. After permeabilization with 1% Triton X-100 in PBS for 30 min at room temperature, cells were blocked in 5% (w/v) BSA in PBS and incubated with primary mouse monoclonal NF-jB P65 antibody (1 : 300 dilution, Santa Cruz Biotechnology) at 4°C for 16 h. After incubation with primary antibody and washing with PBS for 5 min three times, cells were incubated with fluorescein isothiocyanate-conjugated secondary antibodies (1 : 500) in PBS away from light for 1 h at room temperature. The nuclei were stained with DAPI (10 lgÁmL À1 ). Cells were analyzed using confocal laser scanning microscope (Zeiss LSM 700, Oberkochen, Germany).
